← Back to Search

Radiation Therapy

GRID Therapy for Advanced Cancer

N/A

Recruiting

Led By Te Vuong, MD

Research Sponsored by Sir Mortimer B. Davis - Jewish General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patient planned to undergo palliative radiation therapy treatments to one of the following 5 sites: extremities, neck, chest, abdomen and pelvis

WHO performance status of 0-2

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3, 6, 9, 12 months

Awards & highlights

Study Summary

This trial is testing a new way of giving radiation therapy to people with tumors that are hard to treat. The new method is called spatially fractionated radiation (SFR). It delivers one single treatment through a grid containing holes. The goal of the trial is to see if SFR is a safe and effective way to palliate patients with symptomatic bulky tumors.

Who is the study for?

This trial is for adults aged 18+ with confirmed malignancies, who have bulky tumors larger than 8cm or tumors resistant to radiation like melanoma. It's also for those previously treated with palliative radiation needing more than one fraction. Patients must be able to consent and have a WHO performance status of 0-2. Pregnant women, patients with brain/spinal cord tumors, previous hypofractionated radiation therapy, or curable conditions are excluded.Check my eligibility

What is being tested?

The trial tests spatially fractionated radiation therapy (SFR) as a single-session treatment through a grid for symptomatic bulky or radioresistant tumors. The goal is to validate SFR's safety and effectiveness compared to traditional multiple-session palliative treatments that can cause significant toxicity.See study design

What are the potential side effects?

While the side effects specific to SFR aren't detailed here, typical side effects from similar palliative radiation therapies may include skin reactions at the treatment site, fatigue, nausea, and potential damage to nearby organs depending on tumor location.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am scheduled for radiation therapy on my limbs, neck, chest, abdomen, or pelvis for symptom relief.

Select...

I can take care of myself and perform light activities.

Select...

I am 18 years old or older.

Select...

My tumor is larger than 8cm, resistant to radiation, or was previously treated with radiation.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3, 6, 9, 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3, 6, 9, 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3, 6, 9, 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Symptom relief, as measured using the CTCAE grading system (v4.0) and pain questionnaire

Secondary outcome measures

Acute toxicity of treatment, as measured using the CTCAE grading system (v4.0)

Cost-effectiveness, as measured by evaluating the cost of the procedure per patient and the efficacy of treatment with regards to symptom relief and tumor response

Long-term toxicity of treatment, as measured using the CTCAE grading system (v4.0)

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: GRID radiation therapyExperimental Treatment1 Intervention

A single dose of 15-20Gys of spatially fractionated radiation therapy

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Sir Mortimer B. Davis - Jewish General HospitalLead Sponsor

55 Previous Clinical Trials

21,110 Total Patients Enrolled

Te Vuong, MDPrincipal InvestigatorSir Mortimer Jewish General Hospital

6 Previous Clinical Trials

387 Total Patients Enrolled

Media Library

Spatially Fractionated Radiation Therapy (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02333110 — N/A

Tumors Research Study Groups: GRID radiation therapy

Tumors Clinical Trial 2023: Spatially Fractionated Radiation Therapy Highlights & Side Effects. Trial Name: NCT02333110 — N/A

Spatially Fractionated Radiation Therapy (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02333110 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still availability for participants in this trial?

"Correct. Clinicaltrials.gov states that this investigation is currently looking for participants, which was initially made public on January 1st 2015 and last edited on April 7th 2022. The study requires 50 individuals to be recruited from one single clinical site."

Answered by AI

What is the upper limit of participants for this research project?

"Indeed, the data on clinicaltrials.gov suggests that this trial is presently recruiting participants. It was initially posted on January 1st 2015 and last updated April 7th 2022; 50 patients are needed from a single medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

GRID Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors

Dr. Te Vuong 2015. "GRID Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02333110.